Multiple sclerosis and spasticity: the role of anaesthetic nerve blocks on rectus femoris muscle. When should stiff knee be treated with botulinum toxin?
DOI:
https://doi.org/10.2340/jrm.v56.40437Keywords:
Botulinum toxin, Multiple sclerosis, Nerve blocks, Personalized medicine, Spasticity, RehabilitationAbstract
Objective: To compare the effect of rectus femoris diagnostic motor nerve blocks (DNB) with anaesthetics and rectus femoris muscle botulinum toxin (BoNT-A) injection in multiple sclerosis patients with unilateral stiff-knee gait.
Design: Prospective observational study
Subjects/Patients: Multiple sclerosis patients in stable condition.
Methods: Patients underwent evaluation before and 1 hour after the anaesthetic block, and 1 month after the botulinum injection. Assessment included a 10-m walking test, a 6-minute walking test, a timed-up-and-go (TUG) test, and a Baseline Expanded Disability Status Scale (EDSS). Post-DNB and post-BoNT-A satisfaction was measured with the global assessment of efficacy scale.
Results: Fourteen patients with unilateral stiff-knee gait due to multiple sclerosis underwent a DNB, among whom 13 received botulinum injections in the rectus femoris muscle after a satisfying test result. Positive post-DNB results correlated with significant functional improvements after BoNT-A. Higher EDSS and longer time from diagnosis correlated with poorer post-DNB and post-BoNT-A absolute outcomes.
Conclusion: DNB showed predictive value for BoNT-A outcomes, especially in the case of worse functional status. It effectively predicted endurance and walking speed improvement, while TUG showed greater improvement after botulinum. In cases of uncertain therapeutic benefit, nerve blocks may provide a valuable diagnostic support, particularly in patients with lower functional status.
Downloads
References
Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502–1517.
https://doi.org/10.1016/S0140-6736(08)61620-7 DOI: https://doi.org/10.1016/S0140-6736(08)61620-7
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, 3rd ed. Mult Scler 2020; 26: 1816–1821.
https://doi.org/10.1177/1352458520970841 DOI: https://doi.org/10.1177/1352458520970841
Baricich A, Battaglia M, Cuneo D, Cosenza L, Millevolte M, Cosma M, et al. Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: an observational longitudinal study. Front Neurol 2023; 14: 1133390.
https://doi.org/10.3389/fneur.2023.1133390 DOI: https://doi.org/10.3389/fneur.2023.1133390
Hughes C, Howard IM. Spasticity management in multiple sclerosis. Phys Med Rehabil Clin N Am 2013; 24: 593–604.
https://doi.org/10.1016/j.pmr.2013.07.003 DOI: https://doi.org/10.1016/j.pmr.2013.07.003
Baricich A, Wein T, Cinone N, Bertoni M, Picelli A, Chisari C, et al. BoNT-A for post-stroke spasticity: guidance on unmet clinical needs from a Delphi Panel approach. Toxins 2021; 13: 236.
https://doi.org/10.3390/toxins13040236 DOI: https://doi.org/10.3390/toxins13040236
Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type A in adult spas-ticity. J Rehabil Med 2009; 41: 13–25.
https://doi.org/10.2340/16501977-0303 DOI: https://doi.org/10.2340/16501977-0303
Elovic EP, Esquenazi A, Alter KE, Lin JL, Alfaro A, Kaelin DL. Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. PM R 2009; 1: 842–851.
https://doi.org/10.1016/j.pmrj.2009.08.001 DOI: https://doi.org/10.1016/j.pmrj.2009.08.001
Picelli A, Vallies G, Chemello E, Castellazzi P, Brugnera A, Gandolfi M, et al. Is spasticity always the same? An observational study comparing the fea-tures of spastic equinus foot in patients with chronic stroke and multiple sclerosis. J Neurol Sci 2017; 380: 132–136.
https://doi.org/10.1016/j.jns.2017.07.026 DOI: https://doi.org/10.1016/j.jns.2017.07.026
Wagner JM, Kremer TR, Van Dillen LR, Naismith RT. Plantarflexor weakness negatively impacts walking in persons with multiple sclerosis more than plantar flexor spasticity. Arch Phys Med Rehabil 2014; 95: 1358–1365.
https://doi.org/10.1016/j.apmr.2014.01.030 DOI: https://doi.org/10.1016/j.apmr.2014.01.030
Van Der Walt A, Sung S, Spelman T, Marriott M, Kolbe S, Mitchell P, et al. A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Neurology 2012; 79: 92–99.
https://doi.org/10.1212/WNL.0b013e31825dcdd9 DOI: https://doi.org/10.1212/WNL.0b013e31825dcdd9
Moccia M, Frau J, Carotenuto A, Butera C, Coghe G, Barbero P, et al. Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. Neurol Sci 2020; 41: 2781–2792.
https://doi.org/10.1007/s10072-020-04392-8 DOI: https://doi.org/10.1007/s10072-020-04392-8
Yurgil JL, Hulsopple CD, Leggit JC. Nerve blocks: Part I. Upper extremity. Am Fam Physician 2020; 101: 654–664.
Yurgil JL, Hulsopple CD, Leggit JC. Nerve blocks: Part II. Lower extremity. Am Fam Physician 2020; 101: 669–679.
Facciorusso S, Spina S, Gasperini G, Picelli A, Filippetti M, Molteni F, et al. Anatomical landmarks for ultrasound-guided rectus femoris diagnostic nerve block in post-stroke spasticity. Australas J Ultrasound Med 2023; 26: 236–242.
https://doi.org/10.1002/ajum.12354 DOI: https://doi.org/10.1002/ajum.12354
Robertson JV, Pradon D, Bensmail D, Fermanian C, Bussel B, Roche N. Relevance of botulinum toxin injection and nerve block of rectus femoris to kine-matic and functional parameters of stiff knee gait in hemiplegic adults. Gait Posture 2009; 29: 108–112.
https://doi.org/10.1016/j.gaitpost.2008.07.005 DOI: https://doi.org/10.1016/j.gaitpost.2008.07.005
Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Symposia Specialists Medical Books. Distributed by Year Book Medical Publishers, Miami, FL; 1980. p. 485–494.
Marinelli L, Currà A, Trompetto C, Capello E, Serrati C, Fattapposta F, et al. Spasticity and spastic dystonia: the two faces of velocity-dependent hyper-tonia. J Electromyogr Kinesiol Off J Int Soc Electrophysiol Kinesiol 2017; 37: 84–89.
https://doi.org/10.1016/j.jelekin.2017.09.005 DOI: https://doi.org/10.1016/j.jelekin.2017.09.005
Pearson M, Dieberg G, Smart N. Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil 2015; 96: 1339–1348.e7.
https://doi.org/10.1016/j.apmr.2015.02.011 DOI: https://doi.org/10.1016/j.apmr.2015.02.011
Baricich A, Grana E, Carda S, Santamato A, Cisari C, Invernizzi M. High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis. J Neural Transm Vienna Austria 1996 2015; 122: 1283–1287.
https://doi.org/10.1007/s00702-015-1384-6 DOI: https://doi.org/10.1007/s00702-015-1384-6
Tang A, Eng JJ, Rand D. Relationship between perceived and measured changes in walking after stroke. J Neurol Phys Ther 2012; 36: 115–121.
https://doi.org/10.1097/NPT.0b013e318262dbd0 DOI: https://doi.org/10.1097/NPT.0b013e318262dbd0
Tilson JK, Sullivan KJ, Cen SY, Rose DK, Koradia CH, Azen SP, et al. Meaningful gait speed improvement during the first 60 days poststroke: minimal clinically important difference. Phys Ther 2010; 90: 196–208.
https://doi.org/10.2522/ptj.20090079 DOI: https://doi.org/10.2522/ptj.20090079
Perry J, Garrett M, Gronley JK, Mulroy SJ. Classification of walking handicap in the stroke population. Stroke 1995; 26: 982–989.
https://doi.org/10.1161/01.str.26.6.982 DOI: https://doi.org/10.1161/01.STR.26.6.982
Gautschi OP, Stienen MN, Corniola MV, Joswig H, Schaller K, Hildebrandt G, et al. Assessment of the minimum clinically important difference in the timed up and go test after surgery for lumbar degenerative disc disease. Neurosurgery 2017; 80: 380–385.
https://doi.org/10.1227/NEU.0000000000001320 DOI: https://doi.org/10.1227/NEU.0000000000001320
Maldaner N, Sosnova M, Ziga M, Zeitlberger AM, Bozinov O, Gautschi OP, et al. External validation of the minimum clinically important difference in the timed-up-and-go test after surgery for lumbar degenerative disc disease. Spine 2022; 47: 337–342.
https://doi.org/10.1097/BRS.0000000000004128 DOI: https://doi.org/10.1097/BRS.0000000000004128
Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spas-ticity in patients with multiple sclerosis. Clin Rehabil 2007; 21: 331–337.
https://doi.org/10.1177/0269215507072772 DOI: https://doi.org/10.1177/0269215507072772
Li S. Spasticity, motor recovery, and neural plasticity after stroke. Front Neurol 2017; 8: 120.
https://doi.org/10.3389/fneur.2017.00120 DOI: https://doi.org/10.3389/fneur.2017.00120
Published
How to Cite
License
Copyright (c) 2024 Alessio Baricich, Marco Battaglia, Margherita B. Borg, Alberto Loro, Paola Morlino, Lucia Cosenza, Michele Bertoni, Alessandro Picelli, Andrea Santamato, Thierry Deltombe
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
